The 6th Annual IP Strategy [Virtual Summit]: Boston

October 15, 2020

Risk & Uncertainty: The New Normal for IP
[Virtual Summit]

Seven years after the AIA, and patent professionals are no closer to resolving the legal uncertainty that it created. The global pandemic has created economic and market uncertainty. Court decisions have seemingly increased litigation risk and costs. Quality patents are a must to survive this environment. The legal and market uncertainty adds further pressure to budgets.

How to build a cohesive strategy with options around these legal and budget challenges, which also delivers business results?

Come join your IP peers for a day of learning, benchmarking & networking through panels and break-out groups and head back to the office with actionable insights from the front lines.


Jennifer Burdman
Chief Counsel Technology & Therapeutics, Chief IP Officer, and Deputy General Counsel
Valo Health, Inc.
Jim Flaherty
Senior Vice President & General Counsel
Rhythm Pharmaceuticals
David Kuznick
Senior Legal Counsel, IP Litigation
Dell Technologies
Jeremy Oczek
Bond Schoeneck & King
Cath Coombes
Director, Patents
Charles Sanders
Latham & Watkins LLP
Dan Bikus
Business Development Manager
Ronald Cahill
Barnes & Thornburg LLP
Maya Elbert
Of Counsel
Nelson Mullins Riley & Scarborough LLP
Brad Lawrence
Partner and Co-Chair of the Electrical Engineering Practice
Cantor Colburn LLP
Anthony Bolzan
General Counsel
Fraen Corporation
David Shofi
Chief Legal Officer
Sheila Jain Kaushik
Assistant General Counsel, Director, IP & Global Initiatives
Bart Newland
General Counsel
Atalanta Therapeutics
Saket Sankhla
Lead, International Supply Chain
Chandra Adams
Deputy General Counsel and VP, Legal & Intellectual Property
Surface Oncology Inc.
Denise Lane
Chief of Staff to GC
Boston Scientific
Shaun Montana
Head of Intellectual Property (Americas)
Osram Sylvania
Christopher Stow
Associate General Counsel – Intellectual Property
Aspen Aerogels
Melodie Henderson
Vice President, Intellectual Property Counsel
Sigilon Therapeutics
William Neeley
Senior Director, Head of Intellectual Property
Magenta Therapeutics
Kelly Morgan
VP, Head of Legal
Arbor Biotechnologies


Scroll to Top